Kymera Therapeutics, Inc. (KYMR) DCF Valuation

Kymera Therapeutics, Inc. (KYMR) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Kymera Therapeutics, Inc. (KYMR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to calculate the intrinsic value of Kymera Therapeutics, Inc.? Our (KYMR) DCF Calculator integrates real-world data with extensive customization features, allowing you to refine your forecasts and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 2.9 34.0 72.8 46.8 78.6 124.2 196.3 310.2 490.2 774.7
Revenue Growth, % 0 1059.99 114 -35.71 67.84 58.03 58.03 58.03 58.03 58.03
EBITDA -40.4 -43.7 -97.6 -151.7 -143.2 -124.2 -196.3 -310.2 -490.2 -774.7
EBITDA, % -1376.11 -128.45 -134.07 -323.87 -182.21 -100 -100 -100 -100 -100
Depreciation .8 1.8 2.4 3.0 3.6 11.8 18.6 29.5 46.6 73.6
Depreciation, % 28.12 5.18 3.29 6.36 4.54 9.5 9.5 9.5 9.5 9.5
EBIT -41.2 -45.5 -100.0 -154.6 -146.8 -124.2 -196.3 -310.2 -490.2 -774.7
EBIT, % -1404.23 -133.63 -137.36 -330.23 -186.74 -100 -100 -100 -100 -100
Total Cash 92.0 458.7 567.6 559.5 374.9 124.2 196.3 310.2 490.2 774.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 1.4 .1 2.5 18.8
Account Receivables, % 0 4.21 0.18536 5.42 23.87
Inventories .0 -163.4 -9.0 -12.3 .0 -34.4 -54.4 -85.9 -135.8 -214.6
Inventories, % 0 -480.07 -12.34 -26.16 0 -27.7 -27.7 -27.7 -27.7 -27.7
Accounts Payable 3.3 4.4 4.0 4.3 7.1 33.9 53.6 84.7 133.9 211.6
Accounts Payable, % 111.66 12.83 5.5 9.26 9 27.32 27.32 27.32 27.32 27.32
Capital Expenditure -.5 -9.1 -1.6 -2.8 -34.5 -24.1 -38.1 -60.2 -95.1 -150.3
Capital Expenditure, % -18.13 -26.73 -2.19 -6.06 -43.87 -19.4 -19.4 -19.4 -19.4 -19.4
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -41.2 -43.8 -97.8 -151.7 -146.8 -122.3 -193.2 -305.4 -482.6 -762.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -37.7 111.9 -250.5 -150.3 -203.4 -62.9 -177.9 -281.1 -444.2 -702.0
WACC, % 14.56 14.55 14.55 14.56 14.56 14.56 14.56 14.56 14.56 14.56
PV UFCF
SUM PV UFCF -991.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -716
Terminal Value -5,703
Present Terminal Value -2,891
Enterprise Value -3,882
Net Debt -25
Equity Value -3,857
Diluted Shares Outstanding, MM 58
Equity Value Per Share -66.08

What You Will Get

  • Real Kymera Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Kymera Therapeutics’ fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • Comprehensive Financial Data: Gain access to precise historical performance and future forecasts for Kymera Therapeutics, Inc. (KYMR).
  • Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow metrics.
  • Interactive Dashboard: User-friendly graphs and summaries to effectively present your valuation outcomes.
  • Designed for All Skill Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Kymera Therapeutics data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Kymera Therapeutics’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose Kymera Therapeutics, Inc. (KYMR)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Expertise: A team of industry veterans dedicated to advancing drug development.
  • Robust Pipeline: A diverse range of programs targeting serious diseases.
  • Commitment to Quality: Adherence to the highest standards in research and manufacturing.
  • Collaborative Approach: Partnerships with leading organizations to enhance therapeutic impact.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Kymera Therapeutics stock (KYMR).
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for Kymera Therapeutics (KYMR).
  • Consultants: Deliver professional valuation insights on Kymera Therapeutics (KYMR) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like Kymera Therapeutics (KYMR) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Kymera Therapeutics (KYMR).

What the Template Contains

  • Preloaded KYMR Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.